Thank you, and thanks for joining. I'm very happy today to present our top line 24-month eGFR results from our study of sibeprenlimab in IgA nephropathy. Next slide, please. As you're aware, IgA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results